11 Million Students for Anaemia, Obesity & Dwarfism in Egypt
Over 11 million Egyptian and non-Egyptian primary school students have undergone health screenings across all governorates, with additional medical check-ups provided.
Mar 21, 2025
As part of President Abdel Fattah El-Sisi's nationwide initiative for the early detection of anaemia, obesity and dwarfism, the Ministry of Health and Population has announced that 11 million students in Egyptian schools have been screened for these conditions.
The initiative targets both Egyptian and non-Egyptian primary school students residing in Egypt, aiming to ensure early intervention and treatment. Screenings will continue throughout the current academic year across all governorates.
Beyond basic screenings, students undergo full medical examinations, including weight, height, and haemoglobin measurements to assess overall nutrition levels and detect possible health concerns.
Students diagnosed with any of the conditions will be referred to health insurance clinics, where they will receive free tests and treatment. Each student will also be issued a follow-up card containing their personal data to ensure continued monitoring at health clinics nationwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily News Egypt
6 hours ago
- Daily News Egypt
Egypt becomes first country in Eastern Mediterranean to meet WHO target for hepatitis B control
Egypt has become the first country in the World Health Organization's Eastern Mediterranean Region to meet the WHO target for hepatitis B control, a milestone achievement officially recognized during a ceremony held in Cairo on Sunday. At the event, Deputy Prime Minister and Minister of Health Khaled Abdel Ghaffar received a formal certificate from WHO, confirming Egypt's success in achieving the benchmark for reducing hepatitis B prevalence among children and maintaining sustained vaccine coverage. According to national surveys conducted between 2008 and 2024, hepatitis B prevalence among individuals under 60 has declined by 15% since 2015, while rates among children under ten have dropped by 50%. Notably, prevalence among children under five now stands at below 1%—the threshold established by WHO for hepatitis B control. WHO Regional Director for the Eastern Mediterranean, Hanan Balkhy, praised Egypt's public health infrastructure and long-standing commitment to immunization. She highlighted that Egypt has maintained over 90% coverage of the hepatitis B third-dose vaccine for more than a decade, as well as consistent coverage of the birth dose for five consecutive years. 'This is a turning point in Egypt's healthcare journey,' said Abdel Ghaffar. 'It reflects our national commitment to prevention, immunization, and universal health coverage, in alignment with President Abdel Fattah Al-Sisi's vision for health security.' The success was largely driven by Egypt's Expanded Program on Immunization (EPI), which achieved over 95% vaccine coverage, providing free hepatitis B vaccines to all newborns—Egyptian and non-Egyptian alike. The program also ensures immediate birth doses and immunoglobulin for infants born to hepatitis B-positive mothers. Egypt also expanded immunization access to high-risk populations, including healthcare workers, dialysis patients, people living with HIV, and household contacts of hepatitis B carriers. These efforts were supported by upgrades to the digital infrastructure that improved vaccine tracking, reduced waste, and ensured equitable service delivery across the country. WHO Representative in Egypt, Naeema Al-Gasseer, commended Egypt for its technical capacity and long-term planning. 'Egypt fully deserves this recognition. It is a testament to what can be achieved through coordinated health policy and sustained investment in public health.' Beyond immunization, the Ministry of Health launched the Egyptian Vaccine Manufacturers Alliance (EVMA) to localize vaccine production and strengthen domestic supply chain resilience, a key pillar in Egypt's drive toward health system sustainability. Hesham Sateet, Head of the Unified Procurement Authority, emphasized the importance of securing vaccines and medical supplies through transparent, efficient mechanisms. 'This achievement would not have been possible without the full backing of Egypt's political leadership and the close coordination among state institutions,' he said. Ali El-Ghamrawy, President of the Egyptian Drug Authority, added that local manufacturing and regulatory governance are central to Egypt's broader health strategy, which is aligned with Vision 2030 and the UN Sustainable Development Goals. 'The Egyptian experience proves that with strategic planning, institutional coordination, and political will, even complex public health challenges can be overcome,' Abdel Ghaffar concluded, expressing gratitude to frontline health workers and international partners who supported Egypt's journey.
Egypt Today
13 hours ago
- Egypt Today
Egypt increases health budget to LE 496 Billion in 2024/2025
CAIRO – 2 June 2025: The Information and Decision Support Center (IDSC) under the Egyptian Cabinet has revealed that Egypt has firmly established a robust pharmaceutical manufacturing base in recent years, significantly boosting both technical capabilities and production output. As a result, the country has achieved an impressive 91 percent self-sufficiency in medicine. Today, Egypt is home to more than 179 pharmaceutical factories, including 11 internationally accredited facilities, along with 150 factories for medical supplies, 5 for raw material production, and 4 specialized in biological products. Altogether, the nation operates over 986 pharmaceutical production lines, marking a major leap in local healthcare manufacturing. In a parallel effort to reinforce the healthcare system, the Egyptian government has increased the national health budget by 24.9 percent for the 2024/2025 fiscal year, raising the allocation to approximately LE 496 billion, up from LE 397 billion in 2023/2024. This increase meets the constitutional obligation for healthcare funding in the new state budget. Moreover, the government affirmed its continued commitment to the state-funded medical treatment program, with no interruptions planned. The budget allocated to this program has been raised by 16.1 percent, reaching LE 10.1 billion in 2024/2025, compared to LE 8.7 billion in the previous fiscal year. These developments reflect Egypt's strategic focus on health sovereignty and public wellbeing.
Al-Ahram Weekly
16 hours ago
- Al-Ahram Weekly
During World Thyroid Awareness Week: Merck Launches a New Dosage of Euthyrox 75 Micrograms - Sponsored
As part of its ongoing efforts to raise awareness about thyroid-related diseases, Merck Limited Egypt announced the launch of a new dosage of 'Euthyrox 75 micrograms' in the Egyptian market. This announcement was made during the events of the International Thyroid Awareness Week on May 30, 2025, with the participation of 350 healthcare professionals from across Egypt, in addition to 14 expert speakers and session chairs in the field of endocrinology. Hypothyroidism is one of the most common diseases affecting millions worldwide. Patients suffer from reduced thyroid gland activity, which leads to a drop in thyroid hormone levels in the body. Thyroid disorders are among the most widespread endocrine disorders globally, ranking second only to diabetes, with up to 10% of the population affected—making it a major public health concern. It is also one of the leading causes of fatigue, weight gain, depression, heart problems, and other symptoms. Through this event, Merck aimed to raise awareness about the importance of early diagnosis and effective treatment of thyroid disorders. Treatment using synthetic thyroid hormones such as 'Euthyrox' can help restore hormonal balance. Merck is considered a leading company in the field of healthcare and is committed to its social and medical responsibility toward patients with hypothyroidism. With the launch of the new 75 microgram dosage of 'Euthyrox,' the company reaffirms its ongoing support for patients. Dr. Ibrahim Naguib Al-Ebeirashy, Professor of Internal Medicine and Endocrinology at Qasr Al-Ainy and former Head of Internal Medicine Departments at Qasr Al-Ainy, stated that the availability of the 75 microgram dosage of Euthyrox will benefit patients who require precise dose adjustments to avoid hormonal fluctuations. Dr. Sherif El-Seddawy, General Manager and Executive Director of Merck, confirmed that the launch of the new 'Euthyrox 75 micrograms' dosage reflects continued support for patients, alongside the company's commitment to raising awareness about hypothyroidism. He emphasized Merck's ongoing efforts to accelerate scientific and medical initiatives for the benefit of patients. Furthermore, Merck Limited Egypt praised and appreciated the Egyptian Drug Authority as a strategic partner for its ongoing collaboration and efforts to increase awareness among patients and physicians. Dr. Cyrine Hammami, Regional Head of Cardiometabolic and Endocrine Diseases for the Middle East, Africa, and Russia, expressed the company's pride in launching Euthyrox 75 micrograms in the Egyptian market, emphasizing that raising awareness about hypothyroidism is an important step for the community. In this context, Dr. Mohamed Ismail, Head of the Cardiometabolic and Endocrine Business Unit at Merck Limited Egypt, stated that offering multiple dosage options, such as 75 micrograms, helps patients avoid the complications of manual dose adjustment. Dr. Rania Rafiq, Medical Affairs Director, highlighted that raising awareness about hypothyroidism remains one of the company's top priorities, especially since the symptoms can be vague and often diagnosed only after long periods of suffering. Therefore, shedding light on this occasion is of great importance. Follow us on: Facebook Instagram Whatsapp Short link:
